Soleno Therapeutics (SLNO) Other Non-Current Liabilities (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Other Non-Current Liabilities data on file, last reported at $1.4 million in Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 882.76% year-over-year to $1.4 million in Q1 2026; TTM through Mar 2026 was $1.4 million, a 882.76% increase from a year earlier, with the FY2025 full-year figure at $525000.0, down 96.45% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $1.4 million, up from $525000.0 in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for SLNO reached as high as $14.8 million in Q4 2024 and fell as low as $145000.0 in Q1 2025.
• Historically, Other Non-Current Liabilities has averaged $7.9 million across 5 years, with a median of $9.3 million in 2022.
• Across the five-year window, Other Non-Current Liabilities plunged 98.79% in 2025 and jumped 882.76% in 2026, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $8.8 million in 2022, then soared by 30.72% to $11.5 million in 2023, then grew by 28.07% to $14.8 million in 2024, then sank by 96.45% to $525000.0 in 2025, then jumped by 171.43% to $1.4 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $1.4 million in Q1 2026, $525000.0 in Q4 2025, and $398000.0 in Q3 2025.